News

Re-industrialisation of flavonoids production in Europe

Majors investments have been made in recent years to re-industrialise in Europe the active ingredient flavonoid fraction, a drug used to treat venous diseases.
The aim of the recent industrial facilities is to double some of the active ingredient's production. They will help to bring it to market in large quantities in around a hundred countries where demand is growing rapidlt, while maintaining the strategic goal of ensuring the independence of the European pharmaceutical industry on a global scale.

MAJOR GROUPS AND SME WORKING TOGETHER TO DRIVE PHARMACEUTICAL INNOVATION

Large-scale industrial investment in recent years has meant that many French SMEs are now involved un major projects. Thanks to its cutting-edge technology, AGITEC has been able to support these manufacturers in equipping these new production sites with agitators. This collaboration between major groups and SMEs bears witness to a shared commitment to stimulating innovation and growth in Europe's pharmaceutical sector.

The stirrer shown in the vidéo is a mixer with a double ribbon on the periphery and a worm screw in the centre of the shaft, specially dimensioned for mixing powders in explosive atmospheres, thus meeting the most demanding ATEX standards.
This mixing head is sealed by a latest-generation dual-gas cartridge seal developed by John Crane, a specialist in sophisticated seals for ATEX environments. This component ensures reliable, safe operation, even in the most demanding environments.
The materials making up this agitator are 316L stainless steel and Uranus 45N. The overall finish of the parts in contact with the product is a mechanical polish with a guaranteed roughness of less than 0.8μm Ra. These materials are renowned for their corrosion resistance and durability.

KEY ISSUES FACING THE PHARMACEUTICAL INDUSTRY IN EUROPE

The pharmaceutical industry in Europe is facing major challenges and crucial opportunities. Research and development of innovative medicines remains at the heart of this dynamic, with constant pressure to meet healthcare needs that are evolving at the same pace as population growth.
In addition, strict regulations on the safety and efficacy of medicines, as well as their manufacture, require substancial inestment in clinical trials and compliance. Increased competition, the rise of generics and intellectual property issues add complex dimension to the industry.
Nevertheless, Europe also offers a vast and diversified market, as well as opportunities for strategic partnerships and collaborative innovation. As a result, the pharmaceutical industry in Europe faces a constantly changing landscape, requiring agility, innovation and rigorous compliance to thrive in this crucial health sector.